This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mazumder, A. Articles by Rosenberg, S. A. Search for Related Content PubMed PubMed Citation Articles by Mazumder, A. Articles by Rosenberg, S. A.

Lysis of Fresh Human Solid Tumors by Autologous Lymphocytes Activated in Vitro with Lectins

Surgery Branch, National Cancer Institute [A. M., E. A. G., S. A. R.] and the Department of Cytopathology [H. Z. Z.], Clinical Center, NIH, Bethesda, Maryland 20205

Human peripheral blood lymphocytes (PBL), obtained from patients with a variety of cancers, were incubated in vitro with phytohemagglutinin, concanavalin A, and crude or lectin-free T-cell growth factors. The lectin-activated PBL of nine patients were capable of lysing fresh autologous tumor during a 4-hr ⁵¹Cr release assay. Multiple metastases from the same patient were equivalently lysed by these activated autologous PBL. No lysis of fresh PBL or lectin-induced lymphoblast cell targets was seen, although tumor, PBL, and lymphoblast cells were shown to be equally lysable using allosensitized cells. The activated cells could be expanded without loss of cytotoxicity in crude or lectin-free T-cell growth factors. The generation of cells lytic to fresh autologous tumor was dependent on the presence of adherent cells, although the lytic cell itself was not adherent. Proliferation was not involved in the induction of lytic cells since equal lysis was induced in irradiated and nonirradiated lymphocytes. Lectin was not required in the lytic assay, and the addition of -methyl-D-mannoside to concanavalin A-activated lymphoid cells did not decrease the lysis of fresh tumor cells. Activation by lectin for 3 days appears to be an efficient and convenient method for generating human cells lytic to fresh autologous tumor. These lytic cells may be of value for studies of the cell-mediated lysis of human tumor and possibly for tumor immunotherapy as well.

¹ To whom requests for reprints should be addressed, at Surgery Branch, National Cancer Institute, Building 10, Room 10N116, Bethesda, Md. 20205.

Received 9/ 8/81. Accepted 11/30/81.

This article has been cited by other articles:

				J. M. Kirkwood, A. A. Tarhini, M. C. Panelli, S. J. Moschos, H. M. Zarour, L. H. Butterfield, and H. J. Gogas Next Generation of Immunotherapy for Melanoma J. Clin. Oncol., July 10, 2008; 26(20): 3445 - 3455. [Abstract] [Full Text] [PDF]